Cited by 307Cannabis and Cannabinoid ResearchMedicinal Plant Extracts EffectsPsychedelics and Drug Studies

Effects of cannabidiol (CBD) on regional cerebral blood flow

Crippa, José Alexandre de Souza, Zuardi, Antonio Waldo, Garrido, Griselda E J, Wichert-Ana, Lauro, Guarnieri, Ricardo, Ferrari, Lucas, Azevedo-Marques, Paulo M, Hallak, Jaime Eduardo Cecílio +2 more·2004·Neuropsychopharmacology

Abstract

Animal and human studies have suggested that cannabidiol (CBD) may possess anxiolytic properties, but how these effects are mediated centrally is unknown. The aim of the present study was to investigate this using functional neuroimaging. Regional cerebral blood flow (rCBF) was measured at rest using (99m)Tc-ECD SPECT in 10 healthy male volunteers, randomly divided into two groups of five subjects. Each subject was studied on two occasions, 1 week apart. In the first session, subjects were given an oral dose of CBD (400 mg) or placebo, in a double-blind procedure. SPECT images were acquired 90 min after drug ingestion. The Visual Analogue Mood Scale was applied to assess subjective states. In the second session, the same procedure was performed using the drug that had not been administered in the previous session. Within-subject between-condition rCBF comparisons were performed using statistical parametric mapping (SPM). CBD significantly decreased subjective anxiety and increased mental sedation, while placebo did not induce significant changes. Assessment of brain regions where anxiolytic effects of CBD were predicted a priori revealed two voxel clusters of significantly decreased ECD uptake in the CBD relative to the placebo condition (p<0.001, uncorrected for multiple comparisons). These included a medial temporal cluster encompassing the left amygdala-hippocampal complex, extending into the hypothalamus, and a second cluster in the left posterior cingulate gyrus. There was also a cluster of greater activity with CBD than placebo in the left parahippocampal gyrus (p<0.001). These results suggest that CBD has anxiolytic properties, and that these effects are mediated by an action on limbic and paralimbic brain areas.

Integrity signals

Registry

Crossref · 10.1038/sj.npp.1300340

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In healthy volunteers, CBD has anxiolytic properties associated with action on limbic and paralimbic brain areas.

    “Using functional neuroimaging in healthy volunteers, we have observed that CBD has anxiolytic properties and that these effects are associated with an action on the limbic and paralimbic brain areas (Fusar-Poli et al, 2009a; Crippa et al, 2004).”
  • CBD's effects were associated with the activity of the parahippocampal gyrus and hippocampus.

    “The SPECT analysis of this study and of a previous one with healthy volunteers (Crippa et al, 2004) showed that the CBD effects were associated with the activity of the parahippocampal gyrus and hippocampus.”
  • CBD attenuates regional brain reactivity to fear-inducing stimuli in functional magnetic resonance imaging studies.

    “attenuates regional brain reactivity to fear-inducing stimuli in functional magnetic resonance imaging studies (Crippa et al., 2004; Fusar-Poli et al., 2010).”

    From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Crippa et al., 2004

  • CBD reverses glossophobia (fear of public speaking).

    “and glossophobia (fear of public speaking) (Bergamaschi et al., 2011; Crippa et al., 2004; Zuardi et al., 1993)”

    From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Crippa et al., 2004

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F.
Affiliations
  • Universidade de São Paulo (BR)
  • University of London (GB)
Venue
Neuropsychopharmacology
Published
2003-10-29
Volume
29
Issue
2
Pages
417-426
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2132947706
Cited by
307
References
115
Citations by year
2026: 5 · 2025: 16 · 2024: 23 · 2023: 21 · 2022: 25 · 2021: 22 · 2020: 33 · 2019: 20 · 2018: 11 · 2017: 16 · 2016: 7 · 2015: 12 · 2014: 7 · 2013: 9 · 2012: 19
FWCI
2.14
Type
journal article
Language
en
Open access
closed
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
cannabidiol, anxiolytic effects, regional cerebral blood flow, subjective anxiety, posterior cingulate cortex, parahippocampal gyrus, limbic system, placebo effect, healthy volunteers
MeSH terms
Adult, Anxiety, Brain Mapping, Cannabidiol, Cerebral Cortex, Cerebrovascular Circulation, Cysteine, Double-Blind Method, Humans, Image Processing, Computer-Assisted, Functional Laterality, Male, Neuropsychological Tests, Pain Measurement, Regional Blood Flow, Time Factors, Anti-Anxiety Agents, Organotechnetium Compounds, Tomography, Emission-Computed, Single-Photon, Radiopharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review